Genomic characterization of 414 thymic carcinomas using the Foundation Medicine platform revealed that the most frequently altered genes were CDKN2A (39.9%), TP53 (30.2%), CDKN2B (24.6%), BAP1 (8.2%), TET2 (8.0%), KIT (8.0%), SETD2 (7.7%), NFKBIA (7.7%), ASXL1 (7.0%), and KMT2D (6.0%). This evidence concerns the gene TET2 and thymic carcinoma.